About doxorubicin hcl
Pegylated liposomal anthracycline chemotherapy
Used for
- Ovarian cancer that has returned after chemotherapy
- Advanced breast cancer when other treatments are unsuitable
- AIDS-related Kaposi sarcoma
- Multiple myeloma, with bortezomib
Usual adult dose
Usually 50 mg/m² intravenously every 4 weeks for ovarian cancer or breast cancer; doses differ for other cancers.
Common side effects
- Hand-foot syndrome, with redness, pain, or peeling
- Mouth sores, nausea, or diarrhea
- Low blood cell counts and increased infection risk
- Infusion reactions, fatigue, or hair loss
Important warnings
- Can damage the heart; risk rises with lifetime anthracycline exposure.
- Infusion reactions can be severe, especially during the first infusion.
- Can cause serious hand-foot syndrome and mouth sores.
- Requires blood-count, liver-function, and heart monitoring during treatment.
Pregnancy
May harm an unborn baby. Effective contraception is needed during treatment and for 6 months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for 10 days after the final dose.
Interactions
- Other medicines that can damage the heart may increase heart risks.
- Strong CYP3A4 inhibitors or inducers may alter doxorubicin exposure.
- Other chemotherapy or radiation may increase blood-cell suppression or tissue toxicity.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.